New Antibody Cocktail Offers Post-Infection Protection Against Nipah and Hendra Viruses

By Simone Carter

An international research team led by the Icahn School of Medicine at Mount Sinai has developed a monoclonal antibody cocktail that offers complete protection against the lethal Nipah and Hendra viruses, even when administered after infection onset. This breakthrough, detailed in a study published in Science Translational Medicine, marks the first time such post-exposure efficacy has been demonstrated with fully human antibodies.

The cocktail comprises two monoclonal antibodies: anti-RBP (8G3), which targets the receptor-binding protein, and anti-F (2A1), which targets the fusion protein. This dual-targeting approach not only neutralizes the viruses but also shows enhanced resilience against viral escape mutants compared to single-antibody therapies.

In preclinical trials involving hamsters, the antibody cocktail provided complete protection against a lethal Nipah virus challenge, even when treatment was delayed post-infection. The study highlights the significant public health threat posed by these viruses, which have case fatality rates ranging from 40% to 75%.